Oppenheimer & H.C. Wainwright Bullish on LEGN, JBIO, CGEN

Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines.